Short-term administration of prulifoxacin: a preventive strategy to reduce Bacillus Calmette-Guerin (BCG)-induced toxicity in patients with superficial bladder cancer
Completed
- Conditions
- CancerBCG-induced toxicity in patients with superficial bladder cancerMalignant neoplasm of bladder
- Registration Number
- ISRCTN90497703
- Lead Sponsor
- Magna Graecia University of Catanzaro (UMG) (Italy)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
1. Both males and females, age older than 18
2. Intermediate or high risk superficial bladder cancer
3. Indication for BCG intravesical adjuvant therapy after transurethral resection (TUR)
4. Signed informed consent
Exclusion Criteria
1. Patient age older than 85 years
2. World Health Organization (WHO) performance status 3 or 4
3. Previous treatment with BCG during the previous 3 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method